Juvenescence Acquires Ro5 to Integrate AI in Drug Discovery and Development
Juvenescence has completed the acquisition of Ro5, a move aimed at strengthening its artificial intelligence and machine learning capabilities in drug discovery and development. The acquisition is expected to…
From the Biotech Insider archive. This article dates from Jun 14, 2025 and is preserved as first published.
Juvenescence has completed the acquisition of Ro5, a move aimed at strengthening its artificial intelligence and machine learning capabilities in drug discovery and development. The acquisition is expected to bolster Juvenescence’s research and development efforts by integrating advanced AI-driven technologies into its operations.
The acquisition is expected to bolster Juvenescence’s research and development efforts by integrating advanced AI-driven technologies into its operations.
Ro5 specializes in AI and machine learning applications within pharmaceutical research, focusing on streamlining processes and improving efficiency in drug discovery. By incorporating Ro5’s expertise, Juvenescence seeks to enhance its ability to identify potential therapeutic candidates more effectively. This strategic acquisition aligns with broader industry trends that emphasize the use of AI to accelerate innovation in medicine while reducing costs associated with traditional methods of drug development.
